Title: Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery
Authors: Whellan, David J ×
Tricoci, Pierluigi
Chen, Edmond
Huang, Zhen
Leibowitz, David
Vranckx, Pascale
Marhefka, Gregary D
Held, Claes
Nicolau, Jose C
Storey, Robert F
Ruzyllo, Witold
Huber, Kurt
Sinnaeve, Peter
Weiss, A. Teddy
Dery, Jean-Pierre
Moliterno, David J
Van de Werf, Frans
Aylward, Philip E
White, Harvey D
Armstrong, Paul W
Wallentin, Lars
Strony, John
Harrington, Robert A
Mahaffey, Kenneth W #
Issue Date: Mar-2014
Publisher: Elsevier Biomedical
Series Title: Journal of the American College of Cardiology vol:63 issue:11 pages:1048-1057
Article number: 10.1016/j.jacc.2013.10.048
Abstract: This study evaluated effects of protease-activated receptor-1 antagonist vorapaxar (Merck, Whitehouse Station, New Jersey) versus placebo among the TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) study patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass grafting (CABG).
ISSN: 0735-1097
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Cardiology
Field of Study Social and Community Work Odisee
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science